Researchers discover new immunotherapy combination effective at killing cancer cells

August 29, 2017 by Kelly Johnston, University of Calgary
Researchers discover new immunotherapy combination effective at killing cancer cells
“We’ve been looking at these cancer drugs the wrong way — as tumour-targeting drugs — instead of what we now feel is their most important biological role: as immune stimulating therapy,” says University of Calgary researcher and the study's principal investigator Doug Mahoney.  Credit: Doug Mahoney’s Lab

Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body's immune system detect and attack cancerous cells. Doug Mahoney's lab at the University of Calgary recently discovered an immunotherapy that uses existing cancer drugs in a whole new way.

"What we found is a combination of cancer therapies that complement each other in helping the immune system clear the cancer," says Mahoney, PhD, assistant professor in the departments of Microbiology, Immunology and Infectious Diseases, and Biochemistry and Molecular Biology at the Cumming School of Medicine and member of the Arnie Charbonneau Cancer and Alberta Children's Hospital Research Institutes. "Our results suggest that we've been looking at these the wrong way—as tumour-targeting drugs—instead of what we now feel is their most important biological role: as immune stimulating ."

Learning how to ramp up the immune system

Cancer are smart; they know how to hide from the body's own immune system. Cancer cells also know how to control certain immune cells. Like a cruel form of mind control, some cancerous tumours can reprogram some immune cells to "block" other immune cells from attacking, leaving the tumour free to grow.

Treatments aimed at revving up the immune system's attack on the cancer may be the most promising approach to cancer therapy since combination chemotherapy. Yet studies have shown single therapies targeting only one part of the immune system have been effective in only a small percentage of patients. Results from Mahoney's research study are consistent with many other recent findings that smart combinations of therapies are even more effective in battling some cancers.

Researchers discover new immunotherapy combination effective at killing cancer cells
Doug Mahoney, left, with Dae-Sun Kim, PhD, the study’s lead author. Credit: University of Calgary

For this study, researchers combined two therapies, each targeting a different part of the immune system. The first is an injection of a man-made virus. That injection puts the "gas on" the immune system followed by a second injection of a being developed as a chemotherapy. That drug stops the tumour from reprogramming immune cells.

"The combination of the drugs allowed the to do what they're supposed to. We were able to cure cancer in 20 to 60 per cent of our animal models," adds Mahoney. "It's a very promising result against two very deadly forms of cancer: an aggressive breast cancer and a rare pediatric muscle cancer."

When the researchers added a third complementary , the cure rate went as high as 80 to 100 per cent. Results of the study are published in Nature Communications.

Drugs seen in a new light after two decades

"These results change a lot," says Mahoney. "What's interesting is that neither drug was developed as an immunotherapy. For nearly two decades they have been studied for their ability to directly kill . In viewing these drugs through the lens of immunotherapy, it will impact the way we study them and try to figure out how to make them work better. From a clinical perspective, it changes the way we will try to translate these drugs," says Mahoney.

Mahoney says we'll know more about the impact this study will have on patients in the next five years. His lab is one of three in the world looking at this immunotherapy combination. In the other two locations, clinical trials are about to start based on a similar results.

Explore further: Immune cells the missing ingredient in new bladder cancer treatment

More information: Dae-Sun Kim et al. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms, Nature Communications (2017). DOI: 10.1038/s41467-017-00324-x

Related Stories

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Study sheds light on why some breast cancers have limited response to immunotherapy

August 21, 2017
UNC Lineberger Comprehensive Cancer Center researchers have identified a possible reason why some aggressive breast cancers are unresponsive to certain immunotherapy treatments, as well as a potential solution.

Identifying a novel target for cancer immunotherapy

April 12, 2017
Targeting a molecule called B7-H4—which blocks T-cells from destroying tumor cells—could lead to the development of new therapies that boost the immune system's ability to fight cancer, according to a review published ...

Cancer cells play hide-and-seek with immune system

June 29, 2016
When the immune system attacks cancer, the tumour modifies itself to escape the immune reaction. Researchers at LUMC published on this subject in Nature on 28 June.

Chemotherapy may boost immunotherapy power in ovarian cancer

June 15, 2016
Women with advanced ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy, according to a new study published in Clinical Cancer Research today.

New treatment hope for women with BRCA1 breast cancers

June 7, 2017
Researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient's immune system, to treat an aggressive form of breast cancer.

Recommended for you

Research shows possible new target for immunotherapy for solid tumors

April 24, 2018
Research from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.

Changes in breast tissue increase cancer risk for older women

April 24, 2018
Researchers in Norway, Switzerland, and the United States have identified age-related differences in breast tissue that contribute to older women's increased risk of developing breast cancer. The findings, published April ...

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Experimental arthritis drug prevents stem cell transplant complication

April 24, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows. ...

Scientists develop a new model for glioblastoma using gene-edited organoids

April 24, 2018
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't ...

Technology used to map Mars now measuring effect of treatment on tumours

April 24, 2018
A machine learning approach for assessing images of the craters and dunes of Mars, which was developed at The University of Manchester, has now been adapted to help scientists measure the effects of treatments on tumours.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.